by Admin | Nov 12, 2020 | Portfolio News
Oncolytic viruses hold promise as cancer treatments due to their cancer-killing prowess and ability to be combined with other therapies. But few drugs derived from oncolytic viruses have made it to the market. Arizona State University spinout OncoMyx Therapeutics is...
by Admin | Nov 6, 2020 | Portfolio News
PHOENIX, November 6, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors. Dr. Baum is currently president and chief...
by Admin | Sep 25, 2020 | Portfolio News
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant...
by Admin | Sep 25, 2020 | Portfolio News
SAB to provide strategic guidance for the global development of Clover’s COVID-19 vaccine program Comprised of prominent vaccine and industry experts from around the world September 25, 2020 07:30 AM Eastern Daylight Time CHENGDU, China.–(BUSINESS...
by Admin | Sep 14, 2020 | Delos News, Portfolio News
BEDFORD, Mass., Sept. 14, 2020 /PRNewswire/ — Rejoni announced today that it has closed a $15 million Series A financing. The round was led by Ascension Ventures, with additional participation from Delos Capital and Sparta Group. Rejoni is using its...
by Admin | Sep 1, 2020 | Portfolio News
ATLANTA, Sept. 1, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today the publication of preclinical...
by Admin | Jul 8, 2020 | Portfolio News
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00...
by Admin | Jun 19, 2020 | Portfolio News
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019 GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical...
by Admin | Jun 19, 2020 | Portfolio News
After teaming up with GlaxoSmithKline and Dynavax early on in the pandemic, Chinese biotech Clover Biopharmaceuticals has started trials of its COVID-19 vaccine and expects data in August. The company said the first participants have been dosed in its first clinical...
by Admin | Jun 7, 2020 | Portfolio News
June 07, 2020 09:00 PM Eastern Daylight Time BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24...